Sugarlo Plus 50/500 mg 30 tablets
132£
View analogs-For the treatment of type 2 diabetes mellitus in adults already receiving vildagliptin and metformin as separate tablets.
-In combination with sulfonylureas when diet, exercise, and dual therapy with metformin and sulfonylurea do not provide adequate glycemic control.
-In combination with insulin when a stable dose of insulin and metformin fails to provide sufficient blood sugar control.
-Used as an adjunct to diet and exercise.
Buy
Product quantities
Form of Release: Tablets
Product Brand: Al Esraa Pharmaceuticals
Product Categories: Diabetes
Sugarlo Plus 50/500 mg 30 Film-Coated Tablets
Composition:
Each tablet contains:
Vildagliptin 50 mg
Metformin hydrochloride 500 mg
Description:
Sugarlo Plus is a combination oral antidiabetic medication used to treat type 2 diabetes mellitus. It contains two active substances: vildagliptin, a DPP-4 inhibitor that enhances pancreatic islet cell function, and metformin, a biguanide that improves insulin sensitivity and decreases hepatic glucose production. Together, they help lower blood glucose levels and improve glycemic control.
Indications for Use:
-For the treatment of type 2 diabetes mellitus in adults already receiving vildagliptin and metformin as separate tablets.
-In combination with sulfonylureas when diet, exercise, and dual therapy with metformin and sulfonylurea do not provide adequate glycemic control.
-In combination with insulin when a stable dose of insulin and metformin fails to provide sufficient blood sugar control.
-Used as an adjunct to diet and exercise.
Dosage and Administration:
The usual dose is one tablet twice daily, taken with or just after meals.
Maximum daily dose: 2 tablets.
Dosage may be adjusted by the physician based on renal function, concurrent medications (e.g., sulfonylureas), and blood glucose monitoring.
Contraindications:
-Hypersensitivity to vildagliptin, metformin, or any other component of the formulation.
-Severe renal impairment.
-Liver disease or hepatic impairment previously associated with vildagliptin use.
-Conditions with potential for hypoxia (e.g., cardiovascular collapse, recent myocardial infarction, respiratory failure).
-Diabetic ketoacidosis or diabetic coma.
-Type 1 diabetes mellitus.
-Recent use of iodinated contrast agents.
-Children and adolescents under 18 years of age.
Precautions:
Discontinue other metformin-containing products to avoid overdose.
Alcohol intake should be minimized.
Monitor liver (ALT, AST) and renal function regularly.
Use with caution in patients with conditions that predispose to hypoxia (e.g., infection, dehydration).
Side Effects:
Common:
Diarrhea, flatulence, abdominal pain, metallic taste, loss of appetite
Hypoglycemia (especially in combination with sulfonylureas)
Joint pain
Weight gain
Rare:
Rash, pruritus, urticaria
Hepatic dysfunction, hepatitis
Lactic acidosis (with metformin overdose)
Severe allergic reactions (e.g., facial or tongue swelling, breathing difficulties) require immediate medical attention.
Pregnancy and Lactation:
Contraindicated during pregnancy.
Insulin is preferred for managing diabetes during pregnancy.
Breastfeeding should be discontinued while using Sugarlo Plus.
Storage Conditions:
Store below 30°C in a dry place.
Do not use after the expiration date.
Keep out of reach of children.
Packaging:
Carton box containing 30 film-coated tablets (in blisters) and a package insert.
Tags, Keywords:
Active Ingredients:
No comments yet. Be the first to write one.
Your comment will be published after moderation.
You’ll receive a notification to your email when someone replies.
Русский
English
عربي
